UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 947

Sortiert nach

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Annals of oncology, 2019-06, Vol.30 (6), p.970-976

2019

Link zum Volltext

Verfügbarkeit prüfen

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Annals of oncology, 2020-08, Vol.31 (8), p.1030-1039

2020

Link zum Volltext

Verfügbarkeit prüfen

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662

Clinical pharmacology and therapeutics, 2014-07, Vol.96 (1), p.81-89

2014

Link zum Volltext

Verfügbarkeit prüfen

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

Annals of oncology, 2023-09, Vol.34 (9), p.772-782

2023

Link zum Volltext

Verfügbarkeit prüfen

How to calculate the dose of chemotherapy

British journal of cancer, 2002-04, Vol.86 (8), p.1297-1302

GURNERY, H

2002

Link zum Volltext

Verfügbarkeit prüfen

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

Journal of clinical oncology, 1996-09, Vol.14 (9), p.2590-2611

GURNEY, H

1996

Link zum Volltext

Verfügbarkeit prüfen

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

British journal of cancer, 2014-05, Vol.110 (10), p.2462-2471

2014

Link zum Volltext

Verfügbarkeit prüfen

Metformin in prostate cancer: two for the price of one

Annals of oncology, 2011-12, Vol.22 (12), p.2556-2560

2011

Link zum Volltext

Verfügbarkeit prüfen

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

British journal of cancer, 2014-10, Vol.111 (9), p.1802-1809

2014

Link zum Volltext

Verfügbarkeit prüfen

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

Annals of oncology, 2020-02, Vol.31 (2), p.257-265

2020

Link zum Volltext

Verfügbarkeit prüfen

Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype

Clinical pharmacology and therapeutics, 2007-07, Vol.82 (1), p.33-40

2007

Link zum Volltext

Verfügbarkeit prüfen

Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics

Bone marrow transplantation (Basingstoke), 2020-09, Vol.55 (9), p.1862-1864

2020

Link zum Volltext

Verfügbarkeit prüfen

The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer

Annals of surgical oncology, 2020-07, Vol.27 (7), p.2506-2515

2020

Link zum Volltext

Verfügbarkeit prüfen

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Annals of oncology, 2018-10, Vol.29, p.viii724-viii724

2018

Link zum Volltext

Verfügbarkeit prüfen

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

Clinical pharmacology and therapeutics, 2011-06, Vol.89 (6), p.816-820

2011

Link zum Volltext

Verfügbarkeit prüfen

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

Annals of oncology, 2018-10, Vol.29, p.viii309-viii309

2018

Link zum Volltext

Verfügbarkeit prüfen

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

Annals of oncology, 2018-10, Vol.29, p.viii309-viii310

2018

Link zum Volltext

Verfügbarkeit prüfen

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Annals of oncology, 2020-09, Vol.31, p.S559-S560

2020

Link zum Volltext

Verfügbarkeit prüfen

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

ESMO open, 2023-02, Vol.8 (1), p.100749-100749, Article 100749

2023

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

ESMO open, 2024-05, Vol.9 (5), p.102994, Article 102994

2024

Link zum Volltext

Verfügbarkeit prüfen

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Annals of oncology, 2018-10, Vol.29, p.viii320-viii321

2018

Link zum Volltext

Verfügbarkeit prüfen

e‐TC: Development and pilot testing of a web‐based intervention to reduce anxiety and depression in survivors of testicular cancer

European journal of cancer care, 2017-11, Vol.26 (6), p.e12698-n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)

European journal of cancer (1990), 2015-09, Vol.51, p.S487-S487

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Annals of oncology, 2016-12, Vol.27 (12), p.2302-2303

2016

Link zum Volltext

Verfügbarkeit prüfen

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

European journal of cancer (1990), 2006-05, Vol.42 (8), p.1083-1092

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 947

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(753)
Mit Volltextzugriff
(795)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(455)
Life Sciences & Biomedicine
(322)
Humans
(258)
Biological And Medical Sciences
(148)
Male
(133)
Female
(116)
Physical Sciences
(104)
Medical Sciences
(96)
Animals
(93)
Middle Aged
(79)
Adult
(73)
Oncology
(72)
Aged
(64)
Fundamental And Applied Biological Sciences. Psychology
(55)
Exact Sciences And Technology
(48)
General & Internal Medicine
(47)
Mice
(46)
Medicine, General & Internal
(41)
Pharmacology. Drug Treatments
(36)
Environmental Sciences & Ecology
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Ibis
(62)
Annals Of Oncology
(48)
Joint Force Quarterly : Jfq
(48)
Journal Of Clinical Oncology
(22)
Joint Force Quarterly
(17)
Notes And Queries
(15)
The New England Journal Of Medicine
(14)
European Journal Of Cancer
(11)
Nature
(11)
Blood
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

How to calculate the dose of chemotherapy

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

Metformin in prostate cancer: two for the price of one

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype

Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics

The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

e‐TC: Development and pilot testing of a web‐based intervention to reduce anxiety and depression in survivors of testicular cancer

2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

Suchergebnisse filtern